At a glance
- Originator Pfizer
- Developer GSK
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 09 Mar 1999 No-Development-Reported for Rheumatoid arthritis in USA (Unknown route)
- 29 Aug 1996 Preclinical development for Rheumatoid arthritis in USA (Unknown route)